New Sensor Detects Biomarkers for Alzheimer’s & Parkinson’s in Blood

March 21, 2026 Nkechi Okonkwo- Health Editor Health

As global lifespans increase—driven by wider access to vaccines, clean water, education, and healthier lifestyles—so too does the prevalence of neurodegenerative diseases associated with aging. Researchers are actively seeking modern ways to detect these conditions earlier, when interventions may be most effective. A newly developed sensor offers a promising avenue for the early detection of Alzheimer’s and Parkinson’s disease, potentially revolutionizing how these conditions are diagnosed and managed.

A Novel Sensor for Early Biomarker Detection

Scientists at the University of Cádiz in Spain have developed a device capable of detecting levels of dopamine and serotonin in blood serum samples. These neurotransmitters act as biomarkers for neurodegenerative diseases like Alzheimer’s and Parkinson’s, as well as certain types of cancer. The sensor’s design prioritizes sustainability and affordability, utilizing discarded natural materials and requiring minimal energy for fabrication.

The device functions similarly to a blood glucose meter, measuring the concentration of these key brain chemicals. However, interpretation of the results requires a qualified healthcare professional. Key features of the sensor include:

  • Environmental Impact: Constructed from discarded natural materials.
  • Energy Efficiency: Requires less energy to manufacture than an LED lightbulb.
  • Reusability: Designed for repeated leverage after simple surface polishing.
  • Cost-Effectiveness: Estimated production cost of approximately 15 euro cents per device.

From Pine Needles to Nanoparticles

The innovative sensor leverages a unique manufacturing process. Researchers utilize pine needles—specifically the acicular leaves, also known as ‘pinochas’—to extract an aqueous solution. This extract is then used to synthesize gold nanoparticles using high-energy ultrasound technology. This approach builds on previous operate by the team, which successfully used waste materials from geranium leaves and winemaking (pomace) to create similar nanoparticles. The process transforms a soluble gold salt into metallic gold, forming highly reactive nanoparticles approximately 1400 times smaller than the width of a human hair.

These gold nanoparticles, when deposited onto a Sonogel-Carbon electrode, enable the sensor to detect and quantify dopamine and serotonin concentrations in human serum samples. Researchers have demonstrated a high degree of accuracy and reliability in laboratory testing, with results approaching 100% precision in practical applications.

Addressing a Growing Public Health Challenge

The development of this sensor arrives at a critical juncture. The World Health Organization (WHO) and the United Nations (UN) project that by 2030, one in six people globally will be aged 60 or older. This demographic shift is driving a significant increase in the number of individuals affected by neurodegenerative diseases. Alzheimer’s disease, considered a global epidemic, currently affects over 55 million people worldwide, a number projected to reach 78 million by 2030 and 139 million by 2050. Parkinson’s disease, the second most common neurodegenerative disorder, has seen its prevalence double in the last 25 years, with estimates exceeding 25 million cases globally by 2050.

Limitations and Future Directions

While the initial laboratory results are promising, it’s important to acknowledge the limitations of this research. The sensor has been tested in vitro, meaning in a controlled laboratory setting with donated blood samples. Further research is needed to validate its performance in vivo—in living organisms—and to assess its accuracy and reliability in a clinical setting. The sensor currently requires laboratory analysis of blood samples; the next phase of development focuses on miniaturizing the device for potential use in portable, real-time monitoring systems.

Researchers are exploring integrating the sensor into a capsule or patch, similar to continuous glucose monitors used by individuals with diabetes. This would allow for non-invasive, continuous monitoring of dopamine and serotonin levels. The team at the University of Cádiz is also working to refine the sensor’s sensitivity and expand its ability to detect other biomarkers associated with neurodegenerative diseases.

What’s on the Horizon for Neurodegenerative Disease Detection?

The development of this sensor represents a significant step forward in the pursuit of early and accessible diagnostics for Alzheimer’s and Parkinson’s disease. Ongoing research into immunotherapies, including vaccines, also offers potential for both treatment and prevention. Clinical trials are underway to evaluate the efficacy of these vaccines, with initial results showing promise. The combination of innovative diagnostic tools like this new sensor and advancements in therapeutic approaches could significantly improve the lives of individuals affected by these debilitating conditions.

The researchers emphasize that this sensor is not intended to provide a diagnosis on its own. This proves a tool to aid healthcare professionals in the early detection and monitoring of potential neurodegenerative changes, ultimately contributing to more informed clinical decision-making and improved patient care. Individuals concerned about their risk of developing Alzheimer’s or Parkinson’s disease should consult with a qualified healthcare provider for personalized advice and evaluation.